George Rutherford, MD


My research interests are the epidemiology and prevention of infectious and tropical diseases of public health importance, both internationally and domestically, with a primary focus on HIV and AIDS. My work is funded primarily by the Centers for Disease Control and Prevention through the Presidential Emergency Plan for AIDS Relief. I also have smaller projects dealing with the epidemiology of tuberculosis in California, the prevention of childhood injury, immunizations and bioterrorism. I am a member of the AIDS Research Institute's Executive Committee.
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Epidemic Intelligence Service Officer, 1984 - , Centers for Disease Control and Prevention
PGY-4, 1982 - Pediatrics, University of California, San Diego
PGY-3, 1981 - Paediatrics, University of Toronto - Hospital for Sick Children
PGY-1, PGY-2, 1980 - Pediatrics, University of California, San Diego
M.D., 1978 - Medicine, Duke University
B.S., 1975 - Chemistry, Stanford University
A.M., 1975 - History, Stanford Unviersity
A.B., 1974 - Classics, Stanford University
  1. COVID-19 Susceptibility and Outcomes among People Living with HIV in San Francisco.
  2. Correction to: Behind bars: the burden of being a woman in Brazilian prisons.
  3. Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation analysis.
  4. Co-infection, SARS-CoV-2 and influenza: an evolving puzzle.
  5. Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses, a Systematic Review.
  6. Behind bars: the burden of being a woman in Brazilian prisons.
  7. Facial Masking for Covid-19. Reply.
  8. Association of neighborhood parks with child health in the United States.
  9. How History of Medicine Helps Us Understand COVID-19 Challenges.
  10. Political prioritization and the competing definitions of adolescent pregnancy in Kenya: An application of the Public Arenas Model.
  11. Facial Masking for Covid-19 - Potential for "Variolation" as We Await a Vaccine.
  12. HIV Care Continuum and Meeting 90-90-90 Targets: Cascade of Care Analyses of a U.S. Military Cohort.
  13. Will Coronavirus Disease 2019 Become Seasonal?
  14. Estimation of effects of contact tracing and mask adoption on COVID-19 transmission in San Francisco: a modeling study.
  15. Can HIV recent infection surveillance help us better understand where primary prevention efforts should be targeted? Results of three pilots integrating a recent infection testing algorithm into routine programme activities in Kenya and Zimbabwe.
  17. Screening for Park Access during a Primary Care Social Determinants Screen.
  18. The impact of different types of violence on Ebola virus disease transmission during the 2018-2020 outbreak in the Democratic Republic of the Congo.
  20. The Association of Knowledge, Attitudes and Access with Park Use before and after a Park-Prescription Intervention for Low-Income Families in the U.S.
  21. Economic compensation interventions to increase uptake of voluntary medical male circumcision for HIV prevention: A systematic review and meta-analysis.
  22. Service delivery interventions to increase uptake of voluntary medical male circumcision for HIV prevention: A systematic review.
  23. Projections of epidemic transmission and estimation of vaccination impact during an ongoing Ebola virus disease outbreak in Northeastern Democratic Republic of Congo, as of Feb. 25, 2019.
  24. Estimating the impact of violent events on transmission in Ebola virus disease outbreak, Democratic Republic of the Congo, 2018-2019.
  25. Real-time predictions of the 2018-2019 Ebola virus disease outbreak in the Democratic Republic of the Congo using Hawkes point process models.
  26. Immunization coverage among refugee children in Berlin.
  27. Clinic and park partnerships for childhood resilience: A prospective study of park prescriptions.
  28. Neurological, cognitive, and psychological findings among survivors of Ebola virus disease from the 1995 Ebola outbreak in Kikwit, Democratic Republic of Congo: a cross-sectional study.
  29. The Continuing Value of CD4 Cell Count Monitoring for Differential HIV Care and Surveillance.
  30. Projections of Ebola outbreak size and duration with and without vaccine use in Équateur, Democratic Republic of Congo, as of May 27, 2018.
  31. Primary HIV prevention in pregnant and lactating Ugandan women: A randomized trial.
  32. Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned.
  33. Overdose mortality rates in Croatia and factors associated with self-reported drug overdose among persons who inject drugs in three Croatian cities.
  34. Supportive interventions to improve retention on ART in people with HIV in low- and middle-income countries: A systematic review.
  35. Disclosure and Clinical Outcomes Among Young Adolescents Living With HIV in Kenya.
  36. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people.
  37. Understanding why HIV-infected persons disengaged from pre-ART care in Freetown, Sierra Leone: a qualitative study.
  38. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
  39. Feasibility and effectiveness of a brief, intensive phylogenetics workshop in a middle-income country.
  40. Developing WHO guidelines with pragmatic, structured, evidence-based processes: A case study.
  41. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
  42. A meta-analysis of the effect of high weight on asthma.
  43. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.
  44. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.
  45. The Cochrane HIV/AIDS review group and evidence-based practice in nursing.
  46. Surveillance for incident HIV infection: new technology and new opportunities.
  47. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.
  48. Research in the Veterans Health Administration: the report of the Research Realignment Advisory Committee.
  49. Medicaid managed care and public health data.
  50. Progression and clinical outcome of infection due to human immunodeficiency virus.
  51. Cysticercosis: first 12 months of reporting in California.
  52. The draft lottery and AIDS: evidence against increased intravenous drug use by Vietnam-era veterans.
  53. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.
  54. Human immunodeficiency virus infection in tuberculosis patients.
  55. Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals.
  56. The epidemiology of acquired immunodeficiency syndrome.
  57. A model-based estimate of the mean incubation period for AIDS in homosexual men.
  58. Survival patterns of the first 500 patients with AIDS in San Francisco.
  59. Incidence of salmonellosis in patients with AIDS.